Breakthrough Antibiotic Offers Hope Against Superbugs
Researchers have developed a modified version of the antibiotic darobactin, showing effectiveness against drug-resistant bacteria like E. coli in animal trials. This advancement, published in ACS Infectious Diseases, highlights the potential of darobactin D22 as a new treatment option against pathogens that evade current antibiotics. The study, conducted during World Antimicrobial Resistance Awareness Week, demonstrated promising results in zebrafish and mice, suggesting further development towards clinical trials.